Articles

Retail investors were doing what they do best on Wednesday: Buying the dip in SpaceX shares aggressively, even as the company’s stock sank after it released its first earnings report.

The company faces challenges in Europe, which led to a weaker-than-expected revenue forecast.

The Danish company developed the most lucrative new drug the world had ever seen. Then America’s Eli Lilly outmaneuvered it and took control of the diet-drug market.

Jeff Dean, Google’s chief scientist and one of its first employees, is leaving to launch his own company.

What a difference a week makes. The S&P 500 has surged more than 6% over the past five days, its biggest gain since last year’s tariff tantrum.

Morgan Stanley expects $64 billion in capital spending from SpaceX this year. The company is dramatically ramping up AI investments.

SpaceX CEO Elon Musk said his company will only use Nvidia’s chips to build its AI.

The company is keeping costs in check while signaling upbeat growth trends, analysts say.

Researchers at Andromeda Capital Management are worried about the uncertain return on investment for investors who are financing the AI capex bonanza.

The largest part of the economy grew in July at a robust pace, but scattered shortages of key supplies and dogged inflation raised the cost of business and companies responded by keeping a lid on hiring.

Analysts noted that the company delivered muted upside with its results, underwhelmed some investors with its margin outlook and was simply up against high expectations.

Recent deals to have the U.S. take a stake in companies mark something new: Government ownership used as a standing industrial-policy tool rather than an emergency backstop.